FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2626881021> ?p ?o ?g. }

• W2626881021 endingPage "1235" @default.
• W2626881021 startingPage "1226" @default.
• W2626881021 abstract "PurposePhosphoglucomutase-1 deficiency is a subtype of congenital disorders of glycosylation (PGM1-CDG). Previous casereports in PGM1-CDG patients receiving oral D-galactose (D-gal) showed clinical improvement. So far no systematic in vitro and clinical studies have assessed safety and benefits of D-gal supplementation. In a prospective pilot study, we evaluated the effects of oral D-gal in nine patients.MethodsD-gal supplementation was increased to 1.5 g/kg/day (maximum 50 g/day) in three increments over 18 weeks. Laboratory studies were performed before and during treatment to monitor safety and effect on serum transferrin-glycosylation, coagulation, and liver and endocrine function. Additionally, the effect of D-gal on cellular glycosylation was characterized in vitro.ResultsEight patients were compliant with D-gal supplementation. No adverse effects were reported. Abnormal baseline results (alanine transaminase, aspartate transaminase, activated partial thromboplastin time) improved or normalized already using 1 g/kg/day D-gal. Antithrombin-III levels and transferrin-glycosylation showed significant improvement, and increase in galactosylation and whole glycan content. In vitro studies before treatment showed N-glycan hyposialylation, altered O-linked glycans, abnormal lipid-linked oligosaccharide profile, and abnormal nucleotide sugars in patient fibroblasts. Most cellular abnormalities improved or normalized following D-gal treatment. D-gal increased both UDP-Glc and UDP-Gal levels and improved lipid-linked oligosaccharide fractions in concert with improved glycosylation in PGM1-CDG.ConclusionOral D-gal supplementation is a safe and effective treatment for PGM1-CDG in this pilot study. Transferrin glycosylation and ATIII levels were useful trial end points. Larger, longer-duration trials are ongoing." @default.
• W2626881021 created "2017-06-23" @default.
• W2626881021 creator A5019797356 @default.
• W2626881021 creator A5022316643 @default.
• W2626881021 creator A5023168562 @default.
• W2626881021 creator A5023722894 @default.
• W2626881021 creator A5024071277 @default.
• W2626881021 creator A5033689719 @default.
• W2626881021 creator A5034969299 @default.
• W2626881021 creator A5035734567 @default.
• W2626881021 creator A5036606578 @default.
• W2626881021 creator A5042250612 @default.
• W2626881021 creator A5044744064 @default.
• W2626881021 creator A5044898027 @default.
• W2626881021 creator A5046584221 @default.
• W2626881021 creator A5051906880 @default.
• W2626881021 creator A5052863191 @default.
• W2626881021 creator A5064738584 @default.
• W2626881021 creator A5065210766 @default.
• W2626881021 creator A5067071222 @default.
• W2626881021 creator A5069582545 @default.
• W2626881021 creator A5072235558 @default.
• W2626881021 creator A5073629521 @default.
• W2626881021 creator A5074303150 @default.
• W2626881021 creator A5076640163 @default.
• W2626881021 creator A5081309225 @default.
• W2626881021 creator A5081761103 @default.
• W2626881021 creator A5081891445 @default.
• W2626881021 creator A5082527521 @default.
• W2626881021 creator A5082865698 @default.
• W2626881021 creator A5085439725 @default.
• W2626881021 date "2017-11-01" @default.
• W2626881021 modified "2023-10-12" @default.
• W2626881021 title "Oral D-galactose supplementation in PGM1-CDG" @default.
• W2626881021 cites W1536948380 @default.
• W2626881021 cites W1970122244 @default.
• W2626881021 cites W1980637602 @default.
• W2626881021 cites W1988316620 @default.
• W2626881021 cites W1999355971 @default.
• W2626881021 cites W2037437401 @default.
• W2626881021 cites W2047146560 @default.
• W2626881021 cites W2062355079 @default.
• W2626881021 cites W2064222888 @default.
• W2626881021 cites W2072257556 @default.
• W2626881021 cites W2074105260 @default.
• W2626881021 cites W2086241911 @default.
• W2626881021 cites W2088895427 @default.
• W2626881021 cites W2090024619 @default.
• W2626881021 cites W2098021536 @default.
• W2626881021 cites W2098544265 @default.
• W2626881021 cites W2101455704 @default.
• W2626881021 cites W2108243420 @default.
• W2626881021 cites W2137596099 @default.
• W2626881021 cites W2139588004 @default.
• W2626881021 cites W2160360025 @default.
• W2626881021 cites W2400725165 @default.
• W2626881021 cites W2474318967 @default.
• W2626881021 cites W4255361792 @default.
• W2626881021 doi "https://doi.org/10.1038/gim.2017.41" @default.
• W2626881021 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5675745" @default.
• W2626881021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28617415" @default.
• W2626881021 hasPublicationYear "2017" @default.
• W2626881021 type Work @default.
• W2626881021 sameAs 2626881021 @default.
• W2626881021 citedByCount "52" @default.
• W2626881021 countsByYear W26268810212017 @default.
• W2626881021 countsByYear W26268810212018 @default.
• W2626881021 countsByYear W26268810212019 @default.
• W2626881021 countsByYear W26268810212020 @default.
• W2626881021 countsByYear W26268810212021 @default.
• W2626881021 countsByYear W26268810212022 @default.
• W2626881021 countsByYear W26268810212023 @default.
• W2626881021 crossrefType "journal-article" @default.
• W2626881021 hasAuthorship W2626881021A5019797356 @default.
• W2626881021 hasAuthorship W2626881021A5022316643 @default.
• W2626881021 hasAuthorship W2626881021A5023168562 @default.
• W2626881021 hasAuthorship W2626881021A5023722894 @default.
• W2626881021 hasAuthorship W2626881021A5024071277 @default.
• W2626881021 hasAuthorship W2626881021A5033689719 @default.
• W2626881021 hasAuthorship W2626881021A5034969299 @default.
• W2626881021 hasAuthorship W2626881021A5035734567 @default.
• W2626881021 hasAuthorship W2626881021A5036606578 @default.
• W2626881021 hasAuthorship W2626881021A5042250612 @default.
• W2626881021 hasAuthorship W2626881021A5044744064 @default.
• W2626881021 hasAuthorship W2626881021A5044898027 @default.
• W2626881021 hasAuthorship W2626881021A5046584221 @default.
• W2626881021 hasAuthorship W2626881021A5051906880 @default.
• W2626881021 hasAuthorship W2626881021A5052863191 @default.
• W2626881021 hasAuthorship W2626881021A5064738584 @default.
• W2626881021 hasAuthorship W2626881021A5065210766 @default.
• W2626881021 hasAuthorship W2626881021A5067071222 @default.
• W2626881021 hasAuthorship W2626881021A5069582545 @default.
• W2626881021 hasAuthorship W2626881021A5072235558 @default.
• W2626881021 hasAuthorship W2626881021A5073629521 @default.
• W2626881021 hasAuthorship W2626881021A5074303150 @default.
• W2626881021 hasAuthorship W2626881021A5076640163 @default.
• W2626881021 hasAuthorship W2626881021A5081309225 @default.
• W2626881021 hasAuthorship W2626881021A5081761103 @default.

• next